Home » Market News » DirectorsTalk Highlights » ‘Disease of 1,000 faces’: Understanding lupus
Immupharma Plc

‘Disease of 1,000 faces’: Understanding lupus

It has been described as a disease of 1,000 faces, affecting some 5 million people worldwide.

TV personality Kris Aquino recently made the news when she admitted she is fighting a “form of lupus” that makes her allergic to “everything in the environment” including trees and high temperatures.

According to the Lupus Foundation of America, lupus is a chronic autoimmune disease that can damage any part of the body including the skin, joints, and/or organs. “Chronic” means that the signs and symptoms tend to last longer than six weeks and often for many years.


ImmuPharma PLC (LON:IMM) is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by High unmet medical need,Low marketing costs and Relatively low development costs


To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.